➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Johnson and Johnson
McKesson
Baxter

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for PF-03715455

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PF-03715455?

PF-03715455 is an investigational drug.

There have been 4 clinical trials for PF-03715455. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Lung Diseases, Obstructive, Lung Diseases, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are nine US patents protecting this investigational drug and one hundred and eighty-two international patents.

Recent Clinical Trials for PF-03715455
TitleSponsorPhase
An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary DiseasePfizerPhase 2
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled AsthmaPfizerPhase 2
Single Dose Lipopolysaccharide (LPS) Study In Healthy VolunteersPfizerPhase 1

See all PF-03715455 clinical trials

Clinical Trial Summary for PF-03715455

Top disease conditions for PF-03715455
Top clinical trial sponsors for PF-03715455

See all PF-03715455 clinical trials

US Patents for PF-03715455

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-03715455   Start Trial Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
PF-03715455   Start Trial Chemical compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
PF-03715455   Start Trial P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (Cambridge, MA)   Start Trial
PF-03715455   Start Trial Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors Pfizer Inc. (New York, NY)   Start Trial
PF-03715455   Start Trial Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-03715455

Drugname Country Document Number Estimated Expiration Related US Patent
PF-03715455 Argentina AR099177 2034-01-24   Start Trial
PF-03715455 Australia AU2015208932 2034-01-24   Start Trial
PF-03715455 Australia AU2017200338 2034-01-24   Start Trial
PF-03715455 Australia AU2018202956 2034-01-24   Start Trial
PF-03715455 Australia AU2019202675 2034-01-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Johnson and Johnson
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.